Achillion Promotes Science Chief Deshpande as New CEO

Achillion Pharmaceuticals Inc. (ACHN), the maker of experimental hepatitis C therapies, said the company’s top scientist Milind Deshpande had been chosen to succeed retiring Chief Executive Officer Michael Kishbauch.

Deshpande, also the president of research and development, will take over after a three-month transition, Achillion said today in a statement. He joined the New Haven, Connecticut-based company in 2001 and has been its top scientist since June 2007. Kishbauch, CEO since July 2004, will remain a member of the company’s board.

Achillion has three drugs in clinical testing for hepatitis C, a liver disease estimated to affect 170 million people worldwide. The company announced April 23 that one of the drugs, ACH-3102, appeared effective in five out of eight patients, reducing the amount of the liver-destroying virus in their bloodstream to undetectable levels after 12 weeks of treatment. It has started a 50-patient trial of the compound with its main hepatitis drug, sovaprevir.

“I am humbled by the board’s decision and excited for the opportunity to bring Achillion into late-stage clinical development,” Deshpande said in the statement.

To contact the reporter on this story: Alex Wayne in Washington at awayne3@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.